Biotech Is Back But The Prognosis Is Iffy
The great dot-com collapse has taught European investors that buying stock in initial public offerings can be a brilliant way to lose money. But European money managers have at least one consolation: stocks in local biotech companies, many of which went public recently, are up 60% for the year. Some biotech plays have returned 500%.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.